Close
The Clinical Trials Team is led by Prof Cath Mummery and runs a number of clinical trials. These treatment trials are vitally important to allow us to develop and test medicines that may slow the progression of diseases causing dementia, or even prevent the onset of symptoms. Most clinical trials involve regular visits to our centre to measure the safety and effects of the drug over time.
Current Trials
Please click here to see our ongoing clinical trials or download our clinical trials brochure to learn more:
Details of our other research projects can be found here.
Why do we do clinical trials?
- To test whether a new drug can slow disease progression and have beneficial effects on symptoms of dementia
- To monitor safety and any potential side-effects
- To assess the effects of a new drug on other indicators of disease progression e.g. levels of amyloid or tau in the brain
- Most studies are “randomised placebo-controlled trials”: participants are randomly assigned to one of two main groups: active drug administration or placebo (no active drug) administration. Neither the participant nor the study team will know which group they have been assigned to during the trial.
- Most of our drugs (or placebos) are administered via intravenous infusion or intrathecally (via lumbar puncture).
If you would like more information about taking part in our clinical trials, please email drctrialenquiries@ucl.ac.uk.
The DRC also actively supports Join Dementia Research which matches participants to appropriate research studies throughout the UK.
